Emergent treatments for β-thalassemia and orphan drug legislations
Enrico Costa(Brigham and Women's Hospital), Lucio Luzzatto(University of Florence), Hubert G. M. Leufkens(Utrecht University), Stefano Rivella(Children's Hospital of Philadelphia), Maria Domenica Cappellini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Eva Alessi(Italian Medicines Agency), Massimo Riccaboni(IMT School for Advanced Studies Lucca), Adriana Chilin(University of Padua)
Cited by 13
Related Papers
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
|New England Journal of Medicine|2006|1.3k
Natural History of Paroxysmal Nocturnal Hemoglobinuria
|New England Journal of Medicine|1995|900
Thalassaemia
|The Lancet|2017|763